Shamburg News · 8-K filed Oct 23, 2026, 4:06 PM EDT

Akebia Therapeutics Receives Nasdaq Notice on Bid Price Deficiency

AKBA · Akebia Therapeutics, Inc.

  • Delisting
  • Materiality: high

On October 21, 2026, Akebia Therapeutics, Inc. received a deficiency letter from the Nasdaq Listing Qualifications Department. The notice states that the common stock closed below $1.00 per share for 30 consecutive business days, failing Nasdaq Listing Rule 5550(a)(2). The company has an initial compliance period until April 19, 2027 to regain compliance, and the notice has no immediate effect on the listing.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Item 3.01, accession 0001517022-26-000075.

Written from the filing by Shamburg Markets. Figures are as reported by the company.